Skip to content
★ Sign in to follow
SJ

S Jackson

GlaxoSmithKline plc
Total declarations
114
Company
1
▲ Purchases (3 ops.)
€69k
▼ Sales (4 ops.)
€130k

Latest filing published 08 Jul 2022 for GlaxoSmithKline plc, €4,876.

Filing timeline

BuySale
S Jackson

Insider track record

Disclosed buys
3
Disclosed sells
4
Signal history

Closed purchases

Market purchases
3

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

S Jackson: trading record in brief

All filings by S Jackson on record concern GlaxoSmithKline plc. In total, 114 filings cover trades dated from 9 April 2019 to 6 July 2022.

Market trades split into 3 purchases (€69k) and 4 sales (€130k). Taken together, the sales exceed the purchases by €61k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 107 share grants. Since January 2022: 2 purchases and 2 sales on the market.

The median purchase comes to €23k.

On 8 July 2022 came the latest disclosure, a share grant for €4,876 in GlaxoSmithKline plc. The clock since the last published purchase (7 June 2022) now reads 1,614 days. Filings reach the RNS (LSE) feed a median of 2 days after the trade. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to S Jackson

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations114 total
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    4,166 GBP22FCA-NSM
    232.599 shares@ £17.90940.4% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4434332-3
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    2,143 GBP22FCA-NSM
    120 shares@ £17.8560.2% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4434280-6
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    252 GBP22FCA-NSM
    14 shares@ £17.98930.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4430446-3
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    141 GBP22FCA-NSM
    8 shares@ £17.65750.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4428921-0
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    899 GBP22FCA-NSM
    51 shares@ £17.6290.1% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4428864-4
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    245 GBP22FCA-NSM
    14 shares@ £17.4750.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4406847-3
  • ▲
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    19,693 GBP0FCA-NSM
    1,142 shares@ £17.2441.7% of flowLondon Stock Exchange ( XLON)ISIN GB0009252882FCA-NSM:4395886-1
    Canonical exit: 28 Aug 2022 (T+90)
  • ▼
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    19,819 GBP34FCA-NSM
    1,150 shares@ £17.23411.7% of flowLondon Stock Exchange ( XLON)ISIN GB0009252882FCA-NSM:4395886-0
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    243 GBP22FCA-NSM
    14 shares@ £17.34360.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4370453-3
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    7,018 GBP22FCA-NSM
    393.287 shares@ £17.84370.6% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4339856-4
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    249 GBP22FCA-NSM
    14 shares@ £17.78790.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4338587-4
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    1,458 GBP22FCA-NSM
    84 shares@ £17.35540.1% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4337075-4
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    69 GBP22FCA-NSM
    4 shares@ £17.3350.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4336980-0
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    3,517 GBP22FCA-NSM
    202 shares@ £17.410.3% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4336971-6
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    8,995 GBP22FCA-NSM
    744 shares@ £12.090.8% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4303984-0
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    245 GBP22FCA-NSM
    16 shares@ £15.32380.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4300801-4
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    0FCA-NSM
    8,006 sharesN/AISIN GB0009252882FCA-NSM:4277167-9
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    59,557 GBP23FCA-NSM
    3,763 shares@ £15.82695.2% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4277167-10
  • ◆
    SVP, Global Communication and CEO OfficeExecutivesGlaxoSmithKline plc
    157,906 GBP23FCA-NSM
    10,050 shares@ £15.71213.7% of flowN/AISIN GB0009252882FCA-NSM:4275812-1
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    0FCA-NSM
    55,106 sharesN/AISIN GB0009252882FCA-NSM:4275767-5
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    102,709 GBP23FCA-NSM
    6,537 shares@ £15.7128.9% of flowN/AISIN GB0009252882FCA-NSM:4275763-6
  • ▼
    SVP, Global Communications & CEO OfficeExecutivesGlaxoSmithKline plc
    20,017 GBP37FCA-NSM
    1,226 shares@ £16.32671.7% of flowLondon Stock Exchange ( XLON)ISIN GB0009252882FCA-NSM:4271800-0
  • ▲
    SVP, Global Communications & CEO OfficeExecutivesGlaxoSmithKline plc
    19,879 GBP0FCA-NSM
    1,218 shares@ £16.3211.7% of flowLondon Stock Exchange ( XLON)ISIN GB0009252882FCA-NSM:4271800-1
    Canonical exit: 11 May 2022 (T+90)
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    260 GBP22FCA-NSM
    16 shares@ £16.270.0% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4269726-4
  • ◆
    SVP, Global Communications and CEO OfficeExecutivesGlaxoSmithKline plc
    4,936 GBP22FCA-NSM
    290.908 shares@ £16.96680.4% of flowLondon Stock Exchange (XLON)ISIN GB0009252882FCA-NSM:4245332-4

25 of 114 declarations